Nanobodies are single-domain antibody fragments derived from camelid heavy-chain antibodies, and they function as compact binding modules that can be engineered for highly specific targeting, delivery, or immune modulation. They are being developed across fibroblast activation protein alpha, prame, amyloid beta, tau, and receptor tyrosine kinases applications, with additional roles in blocking immune checkpoints, crossing the blood brain barrier, and delivering radionuclides. Compared with full-size monoclonal antibodies, they are presented as a smaller, more versatile alternative that can be diversified by crispr or engineered using artificial intelligence driven design. Recent studies highlight a panel of FAPα-specific nanobodies used to build CAR-T cells, a nanobody-based TCR-like CAR-T therapy for PRAME in acute myeloid leukemia, and engineered formats for Alzheimer’s disease drug delivery and targeting of Aβ and tau. Their utility spans cancer immunotherapy, adoptive cell therapies, and neurological disease, reflecting their modular binding domain architecture and suitability for monovalent or multivalent constructs. Overall, nanobodies are emerging as a flexible therapeutic platform for targeted cancer therapy, immunotherapy, and CNS delivery.
Cancer
- A panel of FAPα-specific nanobodies was isolated and used as the binding domain to construct FAPα-targeting CAR-T cells, achieving potent antitumor efficacy in glioblastoma in a 2026 MedComm study (PMID:41930329).
- Nanobody-based targeted cancer therapy and immunotherapy were highlighted as a major therapeutic modality, emphasizing their role as a compact alternative to full-size antibodies (PMID:41936638).
- A novel nanobody-based TCR-like CAR-T therapy was developed to target intracellular PRAME for acute myeloid leukemia, extending nanobody use beyond surface antigens (PMID:41985065).
- Monovalent and multivalent nanobody constructs were described as targeting receptor tyrosine kinases and other cancer-related molecules, supporting broader oncology applications (PMID:41936638).
Neurodegeneration
- Camelid-derived single-domain antibody fragments were described as versatile tools for drug delivery and targeting in Alzheimer’s disease (PMID:41568664).
- Engineered nanobody formats allow specific targeting of amyloid-beta, supporting disease-modifying strategies in Alzheimer’s disease and related amyloidoses (PMID:41568664).
- Engineered nanobody formats also allow specific targeting of tau, indicating utility for tauopathy-focused interventions (PMID:41568664).
- Nanobodies were noted to penetrate the blood-brain barrier, making them attractive for CNS delivery applications (PMID:41568664).
Immunotherapy and Platform Engineering
- Nanobodies were described as a revolutionary alternative to monoclonal antibodies, with advantages in size and engineering flexibility (PMID:41936638).
- They play a pivotal role in immunotherapy by blocking immune checkpoints, linking them to immune modulation strategies (PMID:41936638).
- Nanobody libraries can be diversified using CRISPR-facilitated approaches, enabling rapid generation of new binders (PMID:41936638).
- Artificial-intelligence-driven design was presented as an innovative method for engineering nanobodies with improved specificity or function (PMID:41936638).